Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT)

Urolithiasis is a common bothersome condition with a prevalence of 4–20% and an upward trend is reported in developed countries [1, 2]. Non-contrast enhanced computed tomography (NCCT) is the standard for diagnosing patients with acute flank pain [3]. Low-dose NCCT has emerged as the imaging technique of first choice in the acute setting. It provides both excellent sensitivity of 97% and specificity of 95% for the detection of urinary calculi [4]. NCCT determines accurately location, size, density and skin-to-stone distance, all of which are relevant determinants for treatment decision. With the introduction of technical innovations like dual-energy computed tomography (DECT) acquisition of additional information on chemical stone composition is now possible. The attenuation difference produced by two different x-ray energy spectra is utilized to differentiate uric-acid (UA) calculi from non-uric-acid (non-UA) stones. The post-processing software applied for analysis uses a 3-material decomposition algorithm, which characterizes a calculus as a mixture of UA, calcium and urine. Based on this algorithm, material-specific chromatic image-pixels with an attenuation ratio similar to UA are coloured red, those similar to non-UA stones appear blue. This classification is achieved with high accuracy, which is supported by a reported sensitivity of up to 100% [5‐12]. The fact can be decisive for optimal management as in case of UA stones pharmacological chemolitholysis is preferred to interventional approaches [3].

Of note, ureteral stents are also assigned a specific colour according to their material composition on DECT. The imaging of small stones adjacent to a ureteral stent is a common pitfall in the current diagnostic assessment. The option to display stent and stone in contrasting colour may help to optimize the detection. The colour-coded characteristics of calculi based on chemical composition are well documented, whereas for ureteral stents they do not. The determinants underlying the phenomenon of red and blue stents on DECT scans have not been elucidated yet. In the current work it was our main objective to characterize in vitro the appearance of different stents from various manufacturers using DECT.

Results are demonstrated in Fig. 2a. All polyurethane-based stents showed a blue appearance on DECT, whereas stents composed of silicone were red. The assigned colours were constant over various kVp values. The determined colour according to material composition of various stents from the same manufacturer was consistent throughout our measurements (Table 1). As shown in Fig. 2b, placing a pure calcium oxalate monohydrate stone (blue) of 2 mm in size next to a ureteral stent of blue colour makes it difficult to discern the fragment on both coronal and sagittal reformatted DECT images. Now, using a silicone-based stent, which appears red on DECT, the presence of the stone could be easily detected due to a clear stent-stone-contrast.

Information on chemical stone composition optimizes management of urolithiasis in many ways. As mentioned above, DECT assures identification of UA stones with high accuracy, thus efficient chemolitholysis should be preferred rather than interventional treatment, if it is clinically appropriate and safe. However, the overall incidence of UA stones was estimated to be 11.7% for men and 7% for women [13]. Thus, the clinical impact on management is actually rather low. Furthermore, the unique ability to determine stone types may prevent inefficient treatment options. Extracorporeal shockwave lithotripsy (ESWL) achieves good results for renal stones ≤20 mm, but shockwave-resistant stones composed of calcium oxalate monohydrate or cystine are known negative predictors for success [14]. Both stone types can be identified with high diagnostic accuracy using DECT [15]. In these cases multiple ineffective procedures can be avoided in favour of a more effective treatment modality such as percutaneous nephrolithotomy (PNL).

A distinct appearance of ureteral stents on DECT has been observed, but a systematic analysis of this phenomenon is lacking [16]. In the current study we investigated in vitro a random selection of 36 various samples from 7 manufacturers and we were able to match appearance (blue or red) to material composition of a stent. In our setting polyurethane-based stents were always blue on DECT, stents composed of silicone appeared always red. We further demonstrated that an enhanced stent-stone-contrast by selecting a stent in a different colour than the adjacent stone facilitates safe and easy detection, even for 2 mm calculi. This enhanced stent-stone-contrast allows clear differentiation in both coronal and sagittal images. Without colour coding, as in NCCT, only a contour irregularity may be suggestive of an adjacent stone, which becomes speculative when calculi decrease in size. This diagnostic obstacle may be overcome using color-coding based on a post-processing algorithm as applied in DECT. We demonstrated that a pure calcium oxalate monohydrate stone (blue) of 2 mm could be clearly differentiated from a silicon-based stent (red). Next to a blue stent, the presence of the stone was indicative by a poorly defined irregularity, which was more prominent on the coronal scan. The analysis of other 2 mm stones with different composition but a distinct colour on DECT scans, could always be detected accurately when the stent appeared in contrasting colour.

This feature may be of value in various clinical scenarios for the management of urolithiasis. The advantage of DECT technology aids urologists in stent selection according to stone appearance and assures accurate monitoring of stone patients. It has to be acknowledged, that stenting is indicated only in case of obstructive pyelonephritis, anuria and analgesia not achieved medically. The impact of our findings still needs to be evaluated for the clinical management.

The early results of DECT imaging for the management of urolithiasis are promising, however, due to the infancy of this technology relevant issues still need to be addressed. Certain pitfalls have been reported including reduced specificity for small calculi < 3 mm and patients with large body habitus [17]. With the development of third-generation scanners and modification of protocol settings and post-processing the capacity and potential of the technology is still advancing [18].

Certain limitations of this study need to be acknowledged. First of all, although we present the analysis of the largest stent collection to date with convincing consistency, we cannot exclude that stents from different manufacturers may display a diverse phenotype. Certain coatings might have a profound impact on appearance on DECT. Second, we present mainly in vitro data. Prospective, clinical trails are necessary to confirm our first results in stone patients and to evaluate the true benefit for management.

Polyurethane-based stents are blue and stents composed of silicone appear red using DECT imaging. The enhanced stent-stone-contrast using DECT imaging is an additional feature that may be helpful for stent selection. Whenever available, it can contribute to an easy and accurate monitoring of stone patients. The coloured stent-stone-contrast displayed on DECT improves detection, especially of small calculi < 3 mm next to indwelling ureteral stents. Wherever DECT is available, urologists are encouraged to screen for blue and red stents in their institution and to choose ureteral stents according to stone appearance.